While our study proposes these hub genes as potential novel therapeutic targets, their detailed clinical implications, including potential interactions with existing T2D therapies such as SGLT2 inhibitors, remain to be elucidated. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.